Tumour-intrinsic resistance to immune checkpoint blockade

A Kalbasi, A Ribas - Nature Reviews Immunology, 2020 - nature.com
Abstract 'Immune checkpoint blockade'for cancer describes the use of therapeutic antibodies
that disrupt negative immune regulatory checkpoints and unleash pre-existing antitumour …

The immune contexture in cancer prognosis and treatment

WH Fridman, L Zitvogel, C Sautès–Fridman… - Nature reviews Clinical …, 2017 - nature.com
Immunotherapy is currently the most rapidly advancing area of clinical oncology, and
provides the unprecedented opportunity to effectively treat, and even cure, several …

Cytotoxic CD4+ T cells in cancer: expanding the immune effector toolbox

DY Oh, L Fong - Immunity, 2021 - cell.com
Cytotoxic T cells are important effectors of anti-tumor immunity. While tumor killing is
ascribed to CD8+ T cell function, pre-clinical and clinical studies have identified intra …

Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms

RE Tay, EK Richardson, HC Toh - Cancer gene therapy, 2021 - nature.com
Cancer immunotherapy has revolutionised cancer treatment, with immune checkpoint
blockade (ICB) therapy and adoptive cell therapy (ACT) increasingly becoming standard of …

Predictive biomarkers for checkpoint inhibitor-based immunotherapy

GT Gibney, LM Weiner, MB Atkins - The Lancet Oncology, 2016 - thelancet.com
The clinical development of checkpoint inhibitor-based immunotherapy has ushered in an
exciting era of anticancer therapy. Durable responses can be seen in patients with …

Acquired resistance to immune checkpoint inhibitors

AJ Schoenfeld, MD Hellmann - Cancer cell, 2020 - cell.com
Immune checkpoint inhibitors (ICIs) have rapidly altered the treatment landscape for multiple
tumor types, providing unprecedented survival in some patients. Despite the characteristic …

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

D Liu, B Schilling, D Liu, A Sucker, E Livingstone… - Nature medicine, 2019 - nature.com
Immune-checkpoint blockade (ICB) has demonstrated efficacy in many tumor types, but
predictors of responsiveness to anti-PD1 ICB are incompletely characterized. In this study …

Identification of bacteria-derived HLA-bound peptides in melanoma

S Kalaora, A Nagler, D Nejman, M Alon, C Barbolin… - Nature, 2021 - nature.com
A variety of species of bacteria are known to colonize human tumours,,,,,,,,,–, proliferate
within them and modulate immune function, which ultimately affects the survival of patients …

Mechanisms of immune activation and regulation: lessons from melanoma

S Kalaora, A Nagler, JA Wargo, Y Samuels - Nature Reviews Cancer, 2022 - nature.com
Melanoma, a skin cancer that develops from pigment cells, has been studied intensively,
particularly in terms of the immune response to tumours, and has been used as a model for …

The tumor microenvironment in the response to immune checkpoint blockade therapies

F Petitprez, M Meylan, A de Reyniès… - Frontiers in …, 2020 - frontiersin.org
Tumor cells constantly interact with their microenvironment, which comprises a variety of
immune cells together with endothelial cells and fibroblasts. The composition of the tumor …